文献速递骨肿瘤关节外科

平衡膝关节周围骨巨细胞瘤患者的肿瘤控制与软骨保留:单中心临床报告

Balancing Tumor Control and Cartilage Preservation for Patients with Giant Cell Tumor of Bone Around the Knee: A Clinical Report from a Single Institute.
PubMed 文献 · J Bone Joint Surg Am · 2025-03-06

该单中心回顾性研究纳入2002至2013年治疗的64例膝关节周围骨巨细胞瘤患者,比较病灶内刮除(A组40例)、边缘切除联合单髁骨关节骨移植重建(B组18例)和关节置换重建(C组6例)的长期结果。A组复发率最高(25.0%),但软骨保留和功能较好;B组和C组复发率较低。对于邻近关节软骨且软骨下骨广泛受累的晚期肿瘤,边缘切除联合单髁骨关节骨移植重建可能是可行选择。

要点

  • 病灶内刮除组复发10/40(25.0%),边缘切除联合单髁骨关节骨移植重建组复发1/18(5.6%),关节置换重建组复发0/6。
  • 病灶内刮除组11/40(27.5%)和边缘切除联合单髁骨关节骨移植重建组6/18(33.3%)发生骨关节炎(Kellgren-Lawrence 3或4级)。
  • 病灶内刮除组MSTS平均评分87.9,边缘切除联合单髁骨关节骨移植重建组84.8,关节置换重建组93.3。

核心结论

  • 病灶内刮除虽保留软骨且功能较好,但在本组中与更高的肿瘤复发率相关。
  • 对于邻近关节软骨且软骨下骨明显受累的晚期肿瘤,边缘切除联合单髁骨关节骨移植重建可能是可行选择。
  • 关节置换应保留给双髁受累、严重骨与软骨丢失导致无法保留软骨的患者。

研究设计与样本

  • 单中心回顾性研究,纳入2002至2013年治疗的64例膝关节周围骨巨细胞瘤患者(女34例,男30例;股骨远端37例,胫骨近端27例)。
  • 40例接受病灶内刮除(A组);24例接受边缘切除,其中18例联合单髁骨关节骨移植重建(B组),6例接受关节置换重建(C组)。
  • 最短随访8年,分析肿瘤学状态、临床结果和软骨情况。

主要发现

  • 肿瘤复发最常见于A组(10/40,25.0%),其次为B组(1/18,5.6%)和C组(0/6)。
  • A组11例(27.5%)和B组6例(33.3%)发生骨关节炎(Kellgren-Lawrence 3或4级)。
  • A组5例(12.5%)和B组3例(16.7%)接受全膝关节置换。
  • A组发生骨关节炎的危险因素包括肿瘤位于中央、肿瘤长度>6 cm、肿瘤-软骨距离≤3 mm和软骨下骨受累>50%。
  • B组骨关节炎主要源于术后并发症。

关键数值与推荐

  • A组肿瘤复发10/40(25.0%),B组1/18(5.6%),C组0/6。
  • A组骨关节炎(Kellgren-Lawrence 3或4级)11/40(27.5%),B组6/18(33.3%)。
  • A组全膝关节置换5/40(12.5%),B组3/18(16.7%)。
  • A组骨关节炎危险因素:肿瘤位于中央、肿瘤长度>6 cm、肿瘤-软骨距离≤3 mm、软骨下骨受累>50%。
  • MSTS平均评分:A组87.9,B组84.8,C组93.3。

临床怎么用

  • 作者认为,病灶内刮除虽保留软骨且功能较好,但在本组中与更高的肿瘤复发率相关。
  • 作者认为,对于邻近关节软骨且软骨下骨明显受累的晚期肿瘤,边缘切除联合单髁骨关节骨移植重建可能是可行选择。
  • 作者认为,关节置换应保留给双髁受累、严重骨与软骨丢失导致无法保留软骨的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: When managing aggressive giant cell tumor of bone (GCTB) around the knee joint, surgeons are often caught in a dilemma when determining whether to perform marginal excision or intralesional curettage. The purpose of this study was to report the long-term results of different treatment strategies in our institute. METHODS: We retrospectively reviewed 64 eligible cases (34 female and 30 male) with a GCTB (37 in the distal femur, 27 in the proximal tibia) treated from 2002 to 2013. Forty patients received intralesional curettage (group A). Twenty-four received marginal excision of the tumor, with 18 of them undergoing reconstruction with unicondylar osteoarticular allograft (UOA) (group B) and 6 receiving arthroplasty reconstruction (group C). The minimum follow-up was 8 years, and the oncological status, clinical outcomes, and cartilage condition were analyzed. RESULTS: Tumor recurrence was most common in group A (10 of 40, 25.0%), followed by group B (1 of 18, 5.6%) and group C (0 of 6). Eleven patients in group A (27.5%) and 6 in group B (33.3%) developed osteoarthritis (Kellgren-Lawrence grade 3 or 4). Five patients in group A (12.5%) and 3 patients in group B (16.7%) received total knee arthroplasty. Risk factors for the development of osteoarthritis in group A included a centrally located tumor, tumor length of >6 cm, a tumor-cartilage distance of ≤3 mm, and >50% subchondral bone involvement. In group B, osteoarthritis mostly resulted from postoperative complications. The mean Musculoskeletal Tumor Society (MSTS) score was 87.9 in group A, 84.8 in group B, and 93.3 in group C. CONCLUSIONS: Although intralesional curettage preserved cartilage and resulted in better function, it was associated with a higher tumor recurrence rate in our series. For advanced tumors close to the articular cartilage with significant subchondral bone involvement, marginal excision with UOA reconstruction might be a viable alternative. Arthroplasty should be reserved for patients who have bicondylar involvement with severe bone and cartilage loss making cartilage preservation impossible. LEVEL OF EVIDENCE: Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.

来源:J Bone Joint Surg Am,查看原文。版权归原作者所有。

引用

  1. Chen KL, Chen CF, Wu PK, et al. Balancing Tumor Control and Cartilage Preservation for Patients with Giant Cell Tumor of Bone Around the Knee: A Clinical Report from a Single Institute. J Bone Joint Surg Am. 2025. PMID: 40048502. doi:10.2106/JBJS.23.01478

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。